Home Tags Nectin-4

Tag: Nectin-4

Updated Results from Trial Shows Enfortumab Vedotin + Pembrolizumab to Shrink...

Updated findings from EV-103, a phase Ib/II clinical trials of enfortumab vedotin* (Padcev™; Astellas Pharma/Seattle Genetics) in combination with pembrolizumab (Keytruda®; Merck Sharp &...

Accelerated Approval for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial...

The U.S. Food and Drug Administration (FDA) granted accelerated approval to enfortumab vedotin-ejfv (Padcev™; Astellas Pharma / Seattle Genetics)* for the treatment of adult...
Featured Image: Annual Congress of ESMO 2018. Courtesy: © 2018 European Society for Medical Oncology. Used with permission.

ESMO 2019: Seattle Genetics to Present Initial Data from a Phase...

Less than a week before the start of the annual meeting of the European Society for Medical Oncology (ESMO), to be held September 27...
Astellas Pharma, Exhibition booth during ASCO 2019, held May 31 – June 4, 2019 in Chicago, Ill.| Courtsey: Emila Duaerte / Sunvalley Communication

Enfortumab Vedotin Produces High Tumor Response in Metastatic Urothelial Cancer

Enfortumab vedotin (also known as ASG-22CE), an investigational antibody-drug conjugates being developed by Seattle Genetics in collaboration with Astellas Pharma, showed a positive, high...

Phase I Data of Enfortumab Vedotin in Metastatic Urothelial Cancer Supports...

Updated phase I data for enfortumab vedotin, also known as ASG-22ME or ASG-22CE , studied as monotherapy treatment for metastatic urothelial cancer (mUC) were...

Clinical Phase I Data for ASG-15ME and Enfortumab Vedotin (ASG-22ME) Indicates...

Clinical data for ASG-15ME and Enfortumab vedotin, also known as ASG-22ME and ASG-22M6E,  presented at the American Society of Clinical Oncology's (ASCO) 51st Annual Meeting held June...

Astellas Presents Study-results of two Investigational ADCs in Patients with Metastatic...

With two approved antibody-drug conjugates and a large number of  ADCs in clinical development scientists have made significant advances bringing novel ADC technology to the forefront...